Catalog No.
DHJ31001
Description
Abagovomab is a murine monoclonal anti-idiotypic antibody (molecular weight: 165-175 kDa) that functionally imitates the tumor-associated antigen, CA-125.
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Mouse
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
Mucin-16, CA-125, Ovarian carcinoma antigen CA125, CA125, MUC-16, Ovarian cancer-related tumor marker CA125, MUC16
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q8WXI7
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
ACA125, MEN-2234, CAS: 792921-10-9, anti-idiotypic monoclonal antibody mimicking the CA125 protein
Clone ID
Abagovomab
Abagovomab for ovarian cancer, PMID: 21241213
Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer, PMID: 21322756
Anti-idiotypic antibody abagovomab in advanced ovarian cancer, PMID: 19086842
Immunological response induced by abagovomab as a maintenance therapy in patients with epithelial ovarian cancer: relationship with survival-a substudy of the MIMOSA trial, PMID: 24952307
Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO--the MIMOSA study, PMID: 23478059
A robust immune system conditions the response to abagovomab (anti-idiotypic monoclonal antibody mimicking the CA125 protein) vaccination in ovarian cancer patients, PMID: 28919454
Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer, PMID: 17000686
The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR, PMID: 17005631
Suppressive activity rather than frequency of FoxP3(+) regulatory T cells is essential for CA-125-specific T-cell activation after abagovomab treatment, PMID: 19782714
Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer, PMID: 17606738
Antibody-based immunotherapy for ovarian cancer: where are we at?, PMID: 24285017
Understanding the Unique Attributes of MUC16 (CA125): Potential Implications in Targeted Therapy, PMID: 26527287
The antibody-based CA125-targeted maintenance therapy for the epithelial ovarian cancer: a meta-analysis, PMID: 29894066
Maintenance therapy in ovarian cancer: Molecular basis and therapeutic approach, PMID: 22977486
Forces determining the adsorption of a monoclonal antibody onto an aluminium hydroxide adjuvant: influence of interstitial fluid components, PMID: 19200448
Comparative efficacy of targeted maintenance therapy for newly diagnosed epithelial ovarian cancer: a network meta-analysis, PMID: 31190984
Toll-like receptor 3 is necessary for dsRNA adjuvant effects, PMID: 19195489
For research use only. Not for human or drug use.
